Bruker Balance Sheet Health
Financial Health criteria checks 2/6
Bruker has a total shareholder equity of $1.8B and total debt of $2.3B, which brings its debt-to-equity ratio to 125.1%. Its total assets and total liabilities are $6.1B and $4.3B respectively. Bruker's EBIT is $383.7M making its interest coverage ratio 13.9. It has cash and short-term investments of $157.1M.
Key information
125.1%
Debt to equity ratio
US$2.31b
Debt
| Interest coverage ratio | 13.9x |
| Cash | US$157.10m |
| Equity | US$1.84b |
| Total liabilities | US$4.27b |
| Total assets | US$6.11b |
Recent financial health updates
Recent updates
Bruker's (NASDAQ:BRKR) Anemic Earnings Might Be Worse Than You Think
Nov 14
Bruker: Still Challenged, Certainly Margins
Nov 02Earnings Tell The Story For Bruker Corporation (NASDAQ:BRKR)
Oct 25We Think Bruker (NASDAQ:BRKR) Is Taking Some Risk With Its Debt
Sep 10Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In
Aug 22Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 22Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price
Jun 09Bruker: A Confusing Acquisition Spree
May 31Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations
May 09Bruker Corporation: An Aggressive Acquisition Strategy
Apr 24Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research
Apr 11Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Jan 22There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price
Jan 08Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?
Dec 26Financial Position Analysis
Short Term Liabilities: BRKR's short term assets ($2.2B) exceed its short term liabilities ($1.3B).
Long Term Liabilities: BRKR's short term assets ($2.2B) do not cover its long term liabilities ($2.9B).
Debt to Equity History and Analysis
Debt Level: BRKR's net debt to equity ratio (116.5%) is considered high.
Reducing Debt: BRKR's debt to equity ratio has increased from 59.1% to 125.1% over the past 5 years.
Debt Coverage: BRKR's debt is not well covered by operating cash flow (11.6%).
Interest Coverage: BRKR's interest payments on its debt are well covered by EBIT (13.9x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:55 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bruker Corporation is covered by 35 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Derik de Bruin | BofA Global Research |